Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1995-12-22
1997-12-23
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
514573, 514913, A61K 31215, A61K 3119
Patent
active
057008353
ABSTRACT:
Compositions containing 3-Oxa-D-prostaglandins and methods of their use in treating glaucoma or ocular hypertension are disclosed.
REFERENCES:
patent: 4097489 (1978-06-01), Bundy
patent: 4599353 (1986-07-01), Bito
patent: 5296504 (1994-03-01), Stjernschantz et al.
Goh, Effects Of Prostaglandin D.sub.2 and Its Analogues On Intraocular Pressure In Rabbits, Jpn J. Ophthalmol., vol. 32, pp. 471-480 (1988).
Goh, Effect of topical prostaglandin D.sub.2 on the aqueous humor dynamics in rabbits, Graefe's Archive Clin. Exp. Ophthalmology, vol. 227, pp. 476-481 (1989).
Thierauch, Prostaglandins and their Receptors: II. Receptor and Signal Transduction, Journal of Hypertension, vol. 12, pp. 1-5 (1994).
Nakajima, Effects of Prostaglandin D.sub.2 and its analogue, BW245C, on Intraocular Pressure in Humans, Graefe's Archive Ophthalmology, vol. 229, pp. 441-413 (1991).
Bundy, Synthesis and Platelet Aggregation Inhibiting Activity of Prostaglandin D Analogues, Journal of Medicinal Chemistry, vol. 26, pp. 790-799 (1983).
Alm, The Potential of Prostaglandin Derivatives in Glaucoma Therapy, Current Opinion in Ophthalmology, vol. 4, No. 11, pp. 44-50 (1993). -M.sub.4 Muscarinic Receptors: Use of NMS/OXO-M Ratios to Group Compounds into Potential Agonist, Partial Agonist, and Antagonist Classes, Neurochemistry Research, vol. 20, No. 6, pp. 669-674 (1995).
Sharif, Emedastine: A Potent, High Affinity Histamine H.sub.1 --Receptor-Selective Antagonist for Ocular Use: Receptor Binding andSecond Messenger Studies, Journal of Ocular Pharmacology, vol. 10, No. 4, pp. 653-664 (1994).
Barraclough, Synthesis and Platelet Aggregation Inhibiting Activity of Acid Side-chain Modified Hydantoin Prostaglandin Analogues, Archives in Pharmacology, vol. 326, No. 2, pp. 85-95 (1993).
Jagabandhu Das et al., 9,11-Epoxy-9-homoprosta-5-enoic acid analogues as thromboxane A2 receptor antagonists,, .Med. Chem., vol. 33, pp. 1741-1748 (1990).
Thierauch et al., Prostaglandin D2 and its analogs, Drugs of The Future, vol. 17, No. 9, p. 811, left-hand col., paragraph 4, figure 3 (1994).
Dean Thomas R.
Hellberg Mark
Sallee Verney L.
Alcon Laboratories Inc.
Fay Zohreh
Mayo Michael C.
LandOfFree
3-Oxa-D-prostaglandins for lowering IOP does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-Oxa-D-prostaglandins for lowering IOP, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-Oxa-D-prostaglandins for lowering IOP will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1803127